<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Med Ther</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Med Ther</journal-id><journal-title-group><journal-title>BMC Complementary Medicine and Therapies</journal-title></journal-title-group><issn pub-type="epub">2662-7671</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8086365</article-id><article-id pub-id-type="publisher-id">3305</article-id><article-id pub-id-type="doi">10.1186/s12906-021-03305-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of Green cardamom (<italic>Elettaria cardamomum</italic> Maton) and its combination with cyclophosphamide on Ehrlich solid tumors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Almeer</surname><given-names>Rafa S.</given-names></name><address><email>ralmeer@ksu.edu.sa</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alnasser</surname><given-names>Meshael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aljarba</surname><given-names>Nada</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>AlBasher</surname><given-names>Gadah I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.56302.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 5396</institution-id><institution>Department of Zoology, College of Science, </institution><institution>King Saud University, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.449346.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0501 7602</institution-id><institution>Biology Department, Faculty of Science, </institution><institution>Princess Nourah bint Abdulrahman University, </institution></institution-wrap>Riyadh, Saudi Arabia </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>21</volume><elocation-id>133</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>6</day><month>4</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Cardamom (<italic>Elettaria cardamomum</italic>) is a spice and exhibits potent antioxidant and biological activities through distinct molecular mechanisms. However, the anticancer effect of cardamom was not explored yet in Ehrlich solid tumor (EST)-bearing mice.</p></sec><sec><title>Objectives</title><p id="Par2">This investigation was aimed to evaluate the anti-cancer effects of green cardamom (GCar) alone or combined with the anti-cancer drug cyclophosphamide in an in vivo model to explore its mechanistic role in tumor cell death in EST-bearing mice.</p></sec><sec><title>Methods</title><p id="Par3">Ehrlich ascites tumor cells were injected in the mice and 5&#x02009;days later the animals treated with GCar and/or cyclophosphamide for 10&#x02009;days. Twenty-four hours from the last treatment, animals were sacrificed for the different measurements.</p></sec><sec><title>Results</title><p id="Par4">Data recorded for tumor size, percentage of tumor growth inhibition, tumor growth delay and mean survival time of EST-bearing mice demonstrated the effective role of GCar alone or combined with CPO as a promising anti-cancer agent because it reduced tumor size. GCar elevated the mean survival time of EST-bearing mice compared to that of untreated EST and EST&#x02009;+&#x02009;CPO groups. Analysis of qPCR mRNA gene and protein expression revealed that GCar alone or combined with CPO were promising anticancer agents. After the treatment of EST with GCar, the apoptotic-related genes and proteins were significantly modulated. GCar induced markedly significant decreases in oxidative stress biomarkers and a significant increment in glutathione levels and that of antioxidant enzymes. With a marked diminish in liver and kidney function biomarkers.</p></sec><sec><title>Conclusion</title><p id="Par5">The results revealed that GCar could serve as an apoptotic stimulator agent, presenting a novel and potentially curative approach for cancer treatment, inducing fewer side effects than those of the commercially used anti-cancer drugs, such as CPO.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12906-021-03305-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cardamom</kwd><kwd>Cyclophosphamide</kwd><kwd>Anticancer</kwd><kwd>Toxicity</kwd><kwd>EST-bearing mice</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par30">Chemotherapy is one of the cancer treatment approaches, which may be undertaken alone or together with other therapies, such as surgery and/or radiotherapies. It utilizes a wide range of remedies that have cytotoxic activities to one or more cancerous tissues. Cyclophosphamide (CPO) is an alkylating cytotoxic agent that has been effectively used in patients for the last century for the curing of neoplastic maladies, such as solid tumors and lymphomas, as well as non-neoplastic maladies, such as rheumatoid arthritis and systemic lupus erythrematosus [<xref ref-type="bibr" rid="CR1">1</xref>]. However, the medical use of CPO has been inadequate because of its capability to harm normal tissues, which usually results in toxicity in several organs (heart, testes and urinary bladder) [<xref ref-type="bibr" rid="CR2">2</xref>] Hepatotoxicity is the foremost side effect of CPO because it is metabolized primarily within the hepatocytes by hepatic microsomal cytochrome p450 varied function oxidase system to construct its two-active metabolites phosphoramide mustard (PM) and acrolein. Phosphoramide is linked to the immunosuppressive and antineoplastic outcomes of CPO, while acrolein is associated with the toxic effects of CPO. Studies have indicated that oxidative damage is linked with its hepatotoxic effects [<xref ref-type="bibr" rid="CR3">3</xref>]. CPO toxicity resulting from acrolein binding to the nucleophilic cellular antioxidants, such as glutathione (GSH), results in the exhaustion of the antioxidant defiance molecules and also initiates lipid peroxidation (LPO) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par31">In recent years, many herbal byproducts and phytomedicines have drawn the attention of researchers mainly because of convincing anticancer activities with insignificant side effects [<xref ref-type="bibr" rid="CR5">5</xref>]. Cardamom (<italic>Elettaria cardamomum</italic>) is a spice found in the form of tiny pods with dark seeds. The seeds have strongly sweet and aromatic tastes. Both the seed and the pod have a wealthy smell and are often used in desserts, hot and spicy plates, as well as aromatic beverages, coffees and teas. It is considered as the king of spices and is one of the most luxurious spices, ranking third, with the first and second being saffron (derived from the flower of <italic>Crocus sativus</italic>) and vanilla (derived from orchids of the genus Vanilla), respectively [<xref ref-type="bibr" rid="CR6">6</xref>]. Cardamom is a multi-use spice. It was utilized by ancient Egyptians for its medicinal properties and even for breast-cancer anticipation [<xref ref-type="bibr" rid="CR7">7</xref>]. The pleasant odor profile is an fundamental constituent of cardamom essential oil, the major ingredients of cardamom essential oil are pinene, myrcene, methyl eugenol, 1,8-cineole, a-terpinyl acetate, sabinene, phellandrene, terpinene, limonene, p-cymene, terpinolene, linalool, linalyl acetate, terpinen-4-ol, nerol, citronellol, geraniol, and trans-nerolidal [<xref ref-type="bibr" rid="CR8">8</xref>]. Cardamom has also been used for teeth, gum and throat infection, as well as against lung congestion, pulmonary tuberculosis and digestive disorders [<xref ref-type="bibr" rid="CR9">9</xref>]. Cardamom was found to reduce weight gain and associated metabolic damage to the body [<xref ref-type="bibr" rid="CR10">10</xref>]. Cardamom suppressed edema to a lesser extent, whereas a higher dose of cardamom reveals a more potent anti-inflammatory effect on the skin in the presence of the reference drug, indomethacin [<xref ref-type="bibr" rid="CR11">11</xref>]. The chemopreventive effect of cardamom has also been demonstrated earlier to control colorectal cancer [<xref ref-type="bibr" rid="CR12">12</xref>] and to prevent papillomagenesis on the skin [<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, cardamom extract was found to lessen PTSD-like anxiety symptoms in test animals [<xref ref-type="bibr" rid="CR13">13</xref>]. One study found that when cardamom was consumed during pregnancy, offspring showed enhanced learning, memory, and behavior [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par32">The Ehrlich tumor is a transplantable neoplasm, which corresponds to mammary adenocarcinoma in female. When implanted intraperitoneally, it grows in the ascitic form and when implanted subcutaneously, it grows into a solid tumor. This tumor has been used to grow a tumor model [<xref ref-type="bibr" rid="CR15">15</xref>]. Ehrlich ascites carcinoma (EAC) or Ehrlich solid tumor (EST) model has basically been used for study of tumor pathogenesis and development of anti-tumorigenic agents. In this context, El-Garawani et al. [<xref ref-type="bibr" rid="CR5">5</xref>] and Salah et al. [<xref ref-type="bibr" rid="CR16">16</xref>] were used EAC to study the anticancer effect of <italic>Candelariella vitellina</italic>, and B12 and sitagliptin, respectively.</p><p id="Par33">The aim of this investigation is to examine the possible anticancer efficacies of green cardamom (GCar) alone or in combination with CPO on Ehrlich solid tumor-bearing mice. In addition, the study will extend to examine the protective effects of GCar against CPO-induced hepatotoxicity and nephrotoxicity and determine whether this effect will be modulated through an antioxidant mechanism in the liver and kidney.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Plant material</title><p id="Par34">The seeds of GCar were collected from a local market in Riyadh, Saudi Arabia, in 2019, and were identified and authenticated by a taxonomist from Department of Botany, College of Science, King Saud University. The seeds were powdered with an electrical grinder and then extracted three times by maceration with 70% methanol. The solvent was evaporated using a vacuum evaporator and then lyophilized to remove water [<xref ref-type="bibr" rid="CR17">17</xref>]. The GCar extract was stored at &#x02212;&#x02009;20&#x02009;&#x000b0;C until used. The obtained extract was evaluated with HPLC to determine the phenolics and flavonoids constituents of GCar. The HPLC condition was previously reported by Dkhil et al. [<xref ref-type="bibr" rid="CR18">18</xref>]. The HPLC fingerprint of the GCar revealed the presence of many phenolics and flavonoids compounds, possibly ferulic acid and its derivatives, luteolin, rutin, catechin, caffeic acid, gallic acid and its derivatives, quercetin, and cinnamic acid (Supplementary data; Table <xref rid="MOESM1" ref-type="media">S1</xref>).</p></sec><sec id="Sec4"><title>Ehrlich ascites tumor (EAT) cells</title><p id="Par35">The EAT cell line was sourced from the American Type Tissue Culture Collection (Manassas, VA, USA). EAT cells were counted using a Neubauer hemocytometer with the trypan blue dye exclusion procedure. EAT cells (25&#x02009;&#x000d7;&#x02009;10<sup>5</sup>/mouse) were diluted with 0.2&#x02009;mL of physiological sterile saline solution (0.9% NaCl) and injected intramuscularly (i.m.) in the right thigh of male BALB/c mice.</p></sec><sec id="Sec5"><title>Doses of cardamom and CPO</title><p id="Par36">The dose of cardamom given in this study was 100&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight according to a previous study on the toxicity of this plant by Goyal et al. [<xref ref-type="bibr" rid="CR19">19</xref>]. However, the selected dose of CPO was 50&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight on the basis of a previous study by Twelves et al. [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec6"><title>Experimental animals</title><p id="Par37">Male Swiss albino mice (6&#x02013;8&#x02009;weeks old and weighing 23&#x02009;&#x000b1;&#x02009;4&#x02009;g) were obtained from Biology Department of Princess Nourah bint Abdulrahman University (PNU; Riyadh, Saudi Arabia). Mice were housed under standard laboratory conditions and provided with water and a normal standard basic diet. Mice were acclimatized to experimental conditions for seven-days prior to the experiments. All experimental protocols were in accordance with the handling and care of animals at Princess Nourah bint Abdulrahman University (Approval number: H-01-R-059/19&#x02013;0272, Riyadh, Saudi Arabia). All procedures of this study adhere to the ARRIVE Guidelines for reporting animal research. On day zero, all the mice were injected i.m. with EAT cells and then, on the day four, mice were divided at random into six experimental groups (10 mice per group), as follows:
<list list-type="order"><list-item><p id="Par38">EST untreated control group (Con): Mice were injected intraperitoneally (i.p.) with 0.2&#x02009;ml of physiological saline solution on the 10th day post tumor inoculation (PTI).</p></list-item><list-item><p id="Par39">EST&#x02009;+&#x02009;CPO treated group (CPO): Mice were injected i.p. with a single dose of CPO equal to 50&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight on the 10th day PTI for 3 consecutive days.</p></list-item><list-item><p id="Par40">EST&#x02009;+&#x02009;green cardamom treated group (GCar): Mice were administered orally once daily with GCar at a dose equal to 100&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight for 10&#x02009;days starting on day 5 PTI.</p></list-item><list-item><p id="Par41">EST&#x02009;+&#x02009;green cardamom+CPO combined treated group (GCar-CPO): Mice received an oral dose equal to 100&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight of GCar daily for 5&#x02009;days starting on day 5, on the 10th day PTI they were injected i.p. with a single dose of CPO equal to 50&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight and then they receive a single oral dose equal to 100&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup> body weight of GCar daily for another 5&#x02009;days.</p></list-item></list></p><p id="Par42">The experimental design was followed our previous study [<xref ref-type="bibr" rid="CR15">15</xref>]. Twenty-four hours from the last treatment (day 16 PTI), seven animals of each group were sacrificed by intraperitoneal injection of pentobarbital (200&#x02009;mg&#x02009;kg<sup>&#x02212;&#x02009;1</sup>) and three animals from each group were left to calculate survival time, tumor growth delay time and inhibition of tumor growth.</p></sec><sec id="Sec7"><title>Body weight (BW) changes</title><p id="Par43">Changes in BW were estimated as follows: initial BW was that on day 12 PTI. Final and net final BWs were estimated on day 20 PTI. Net final BW&#x02009;=&#x02009;final BW &#x02013; tumor weight. Percentage difference of BW gain was determined as BW gain ([final BW &#x02013; initial BW]/initial BW)&#x02009;&#x000d7;&#x02009;100. Tumor mass (mg) was determined via the following equation, as demonstrated by Jaganathan et al. [<xref ref-type="bibr" rid="CR21">21</xref>]:</p><p id="Par44">
<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Tumor}\ \mathrm{mass}=\frac{\mathrm{Length}\ \left(\mathrm{mm}\right)\times {\left[\mathrm{Width}\ \left(\mathrm{mm}\right)\right]}^2}{2} $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mtext>Tumor mass</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>Length</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi>mm</mml:mi></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mfenced close="]" open="["><mml:mrow><mml:mtext>Width</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi>mm</mml:mi></mml:mfenced></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:math><graphic xlink:href="12906_2021_3305_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec8"><title>Tumor volume</title><p id="Par45">Tumor volume was determined using the following equation, as mentioned previously [<xref ref-type="bibr" rid="CR15">15</xref>]:</p><p id="Par46">
<disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Tumor}\kern0.17em \mathrm{volume}\left(\mathrm{V}\right)=4/3\prod {\mathrm{r}}_1^2\times {\mathrm{r}}_2{\left(\mathrm{cm}\right)}^3 $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mtext>Tumor&#x02009;volume</mml:mtext><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">V</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mo>/</mml:mo><mml:mn>3</mml:mn><mml:mo>&#x0220f;</mml:mo><mml:msubsup><mml:mi mathvariant="normal">r</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msup><mml:mfenced close=")" open="("><mml:mi>cm</mml:mi></mml:mfenced><mml:mn>3</mml:mn></mml:msup></mml:math><graphic xlink:href="12906_2021_3305_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par47">Where, <italic>r</italic><sub>1</sub> and <italic>r</italic><sub>2</sub> are the radii of tumors in two different planes determined with Vernier calipers.</p></sec><sec id="Sec9"><title>Evaluation of antitumor activity</title><p id="Par48">The tumor growth inhibition ratio (T/C %) was estimated on day 21 by comparing the average values for the treated and untreated tumor-bearing mice. Tumor growth in untreated EST mice was considered to be 100%.</p><p id="Par49">
<disp-formula id="Equc"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{T}/\mathrm{C}\%=\frac{\left(\mathrm{average}\ \mathrm{tumor}\ \mathrm{mass}\ \mathrm{of}\ \mathrm{EST}\ \mathrm{mice}-\mathrm{average}\ \mathrm{tumor}\ \mathrm{mass}\ \mathrm{of}\ \mathrm{treated}\ \mathrm{mice}\right)\times 100}{\mathrm{Average}\ \mathrm{tumor}\ \mathrm{mass}\ \mathrm{of}\ \mathrm{EST}\ \mathrm{mice}} $$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mi mathvariant="normal">T</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>average tumor mass of</mml:mtext><mml:mspace width="0.25em"/><mml:mi>EST</mml:mi><mml:mspace width="0.25em"/><mml:mtext>mice</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>average tumor mass of treated mice</mml:mtext></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mtext>Average tumor mass of</mml:mtext><mml:mspace width="0.25em"/><mml:mi>EST</mml:mi><mml:mspace width="0.25em"/><mml:mtext>mice</mml:mtext></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="12906_2021_3305_Article_Equc.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec10"><title>Percentage increase in life span (ILS)</title><p id="Par50">Mean survival time (MST; <italic>n</italic>&#x02009;=&#x02009;3/group) was estimated by monitoring mortality on a daily basis and the % ILS was estimated via the following equation, as reported previously [<xref ref-type="bibr" rid="CR15">15</xref>]:</p><p id="Par51">
<disp-formula id="Equd"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{MST}=\left(\mathrm{day}\ \mathrm{of}\ \mathrm{first}\ \mathrm{death}+\mathrm{day}\ \mathrm{of}\ \mathrm{last}\ \mathrm{death}\right)/2 $$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mi>MST</mml:mi><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>day</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of first death</mml:mtext><mml:mo>+</mml:mo><mml:mi>day</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of last death</mml:mtext></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math><graphic xlink:href="12906_2021_3305_Article_Equd.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Eque"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \%\mathrm{ILS}=\left(\mathrm{MST}\ \mathrm{of}\ \mathrm{treated}\ \mathrm{group}/\mathrm{MST}\ \mathrm{of}\ \mathrm{EST}-\mathrm{untreated}\ \mathrm{group}\right)\times 100 $$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mo>%</mml:mo><mml:mi>ILS</mml:mi><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>MST</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of treated group</mml:mtext><mml:mo>/</mml:mo><mml:mi>MST</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of</mml:mtext><mml:mspace width="0.25em"/><mml:mi>EST</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mtext>untreated group</mml:mtext></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12906_2021_3305_Article_Eque.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec11"><title>Gene expression analysis</title><p id="Par52">Apoptosis controlled genes expression such as Bcl2, Bax and caspase-3, &#x02212;&#x02009;8 and&#x02009;&#x02212;&#x02009;9, was estimated utilizing &#x003b2;-actin as a reference housekeeper gene. RNA was extracted from the EST samples with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Reverse Transcription System (Promega, Madison, WI, USA) was used to prepare the cDNA. Real-time PCR was performed using SYBR Green Master Mix (Applied Biosystems) on the Applied Biosystems StepOne&#x02122; real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). The PCR was performed as follows: incubation at 95&#x02009;&#x000b0;C for 10&#x02009;min followed by 40&#x02009;cycles for 15&#x02009;s at 94&#x02009;&#x000b0;C, 30&#x02009;s at 58&#x02009;&#x000b0;C and 30&#x02009;s at 70&#x02009;&#x000b0;C. The Pfaffl formula was used for data analysis utilizing the following equation: 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> [<xref ref-type="bibr" rid="CR22">22</xref>]. The primer sets were as follows:</p><p id="Par53">&#x003b2;-actin F: 5&#x02032;-CCA-CCA-TGT-ACC-CAG-GCA-TT-3&#x02032;.</p><p id="Par54">R: 5&#x02032;-AGG-GTG-TAA-AAC-GCA-GCT-CA-3&#x02032;.</p><p id="Par55">Bcl-2&#x02009;F: 5&#x02032;-ACA-GGG-TAC-GAT-AAC-CGG-GA-3&#x02032;.</p><p id="Par56">R: 5&#x02032;-GCC-CAG-ACT-CAC-ATC-ACC-AA-3&#x02032;.</p><p id="Par57">Bax F: 5&#x02032;-GAC-ATT-GGA-CTT-CCT-CCG-GG-3&#x02032;.</p><p id="Par58">R: 5&#x02032;-ACA-GGG-ACA-TCA-GTC-GCT-TC-3&#x02032;.</p><p id="Par59">Caspase-3&#x02009;F:5&#x02032;-GCG-GTT-GTA-GAA-GTT-AAT-AAA-GGT-A-3&#x02032;.</p><p id="Par60">R: 5&#x02032;-AAC-CAG-GTG-CTG-TGG-AGT-AT-3&#x02032;.</p><p id="Par61">Caspase-8&#x02009;F: 5&#x02032;-GGT-TAG-GGG-ACT-CGG-AGA-CT-3&#x02032;.</p><p id="Par62">R: 5&#x02032;-CAG-GCT-CAG-GAA-CTT-GAG-GG-3&#x02032;.</p><p id="Par63">Caspase-9&#x02009;F: 5&#x02032;-TTG-GTG-ATG-TCG-AGC-AGA-AAG-A-3&#x02032;.</p><p id="Par64">R: 5&#x02032;-GGG-ACA-CAA-GTC-ACT-AGC-CC-3&#x02032;.</p></sec><sec id="Sec12"><title>Liver functions parameters</title><p id="Par65">The serum levels of alanine transferase (ALT) and aspartate transferase (AST) were analyzed with a spectrophotometric method [<xref ref-type="bibr" rid="CR23">23</xref>]. Total bilirubin (TB) in serum was assayed using the previously described method [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec13"><title>Kidney function parameters</title><p id="Par66">The levels of kidney function markers (urea and creatinine) in serum were measured using commercial kits purchased from Cayman Chemical (Ann Arbor, Michigan, USA) and the procedures were performed according to the manufacturer&#x02019;s protocols.</p></sec><sec id="Sec14"><title>Oxidative stress biomarkers and antioxidant enzyme activities</title><p id="Par67">Malondialdehyde (MDA) amounts, an indicator for LPO, were assayed in EST tissue homogenates by reaction with thiobarbituric acid [<xref ref-type="bibr" rid="CR25">25</xref>]. Similarly, the homogenates were used to quantify nitric oxide (NO) level [<xref ref-type="bibr" rid="CR26">26</xref>] using Griess reagent and reduced glutathione (GSH) content [<xref ref-type="bibr" rid="CR27">27</xref>] by using Ellman&#x02019;s (5,5&#x02032;-dithiobis-(2-nitrobenzoic acid) or DTNB) reagent. Whereas, glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), and catalase (CAT) were assayed using specific commercial kits obtained from Cayman Chemical and assays procedures were followed the supplier&#x02019;s protocols.</p></sec><sec id="Sec15"><title>Histopathology and immunohistochemistry analyses</title><p id="Par68">Pieces of tumor samples were fixed in 4% neutral paraformaldehyde for 24&#x02009;h. Hematoxylin and eosin (H&#x00026;E) staining for light microscopy was applied. For the recognition of apoptosis controlled proteins, the prepared sections (5&#x02009;&#x003bc;m thickness) were blocked with 0.1% H<sub>2</sub>O<sub>2</sub> for 15&#x02009;min. Then, the specimens were incubated with rabbit polyclonal Bcl-2, Bax or caspases-3 antibody at 4&#x02009;&#x000b0;C during the night. The specimens were rinsed with PBS, incubated with biotinylated goat anti-rabbit immunoglobulins and then with streptavidin&#x02013;peroxidase complexes at 30&#x02009;&#x000b0;C for half an hour. The peroxidase activity was developed with diaminobenzidine (DAB)-hydrogen peroxide. Specimens were captured at 400&#x000d7; magnification.</p></sec><sec id="Sec16"><title>Statistical analysis</title><p id="Par69">Data were represented as the means &#x000b1; standard deviations (SD). Statistical significance was determined by one-way analysis of variance (ANOVA), followed by Duncan&#x02019;s post hoc test. A <italic>p</italic> value &#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec17"><title>Results</title><sec id="Sec18"><title>BW and survival of mice</title><p id="Par70">As shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, EST-inoculated mice treated with GCar, CPO, or GCar-CPO showed a marked (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) decline in BW when compared with that of untreated EST mice. The greatest decline in BW was showed in the CPO-treated mice.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Effects of GCar, CPO and GCar-CPO on body weights of the different treatment groups</p></caption><graphic xlink:href="12906_2021_3305_Fig1_HTML" id="MO1"/></fig></p><p id="Par71">The results indicated that administration of tumor-bearing EST mice with GCar or CPO alone, or in combination markedly decreased tumor development, as recognized by the reduction in tumor volume and tumor weight, compared with those in the tumor-bearing EST mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of CPO, GCar and GCar-CPO on the tumor weight, length, width of the tumor and tumor volume. Values are expressed as means &#x000b1; SD. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig2_HTML" id="MO2"/></fig></p><p id="Par72">Interestingly, we found that MST for the control EST-bearing mice and CPO-treated mice were 13.7 and 14.6&#x02009;days, respectively, which increased to 25 and 24.3&#x02009;days in the GCar and GCar-CPO groups, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Furthermore, ILS for the GCar and GCar-CPO groups increased significantly in comparsion with that for the CPO-treated mice and untreated EST-bearing mice.
<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of CPO, GCar and GCar-CPO on the mean survival time (days) and increase of life span ratio (ILS%). Values are expressed as means &#x000b1; SD. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec19"><title>Histopathology of EST in mice</title><p id="Par73">Healthy mice inoculated with EST cells grew tumor at the site of injection. Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, indicated that slides from EST-bearing mice demonstrated numerous cellular and nuclear pleomorphisms, as could be seen by the compacted and combined tumor cells extend within the muscles tissue, as well as groups of large, round, and polygonal cells with pleomorphic shapes, binucleation, and hyperchromatic nuclei. However, EST-bearing group cured with CPO showed some necrotic areas and the remnant cancer cells encircled the muscles tissue (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). More demolition of EST tissue was found after the oral administration of GCar alone (Fig. <xref rid="Fig4" ref-type="fig">4</xref>c) or in combination with CPO (Fig. <xref rid="Fig4" ref-type="fig">4</xref>d). In these groups, the tumor was sporadic and appeared to be developed slowly and fragmented. Our findings demonstrated that GCar had partial anti-cancer activity.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Muscle fibers between destructed tumor cells (red arrow), fat vacuoles in between tumor cells (white arrow) and remnants of dead tumor cells (apoptotic cells: red arrow; necrotic cells: white star) in the treated mice; compaction and aggregation of the large, round and polygonal tumor cells (green arrow). <bold>a</bold> Control EST, Control EST section shows compaction and aggregation of the large, round and polygonal tumor cells. <bold>b</bold> CPO, <bold>c</bold> EST&#x02009;+&#x02009;GCar and <bold>d</bold> EST&#x02009;+&#x02009;GCar-CPO. All magnifications at &#x000d7;&#x02009;400</p></caption><graphic xlink:href="12906_2021_3305_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec20"><title>qPCR data and immunohistochemistry results</title><p id="Par74">The data represented in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> indicated a significant downregulation in mRNA of Bcl-2 in CPO-treated EST-bearing groups in comparison with that of the control EST-bearing mice. Furthermore, EST-bearing mice treated with GCar mixed with CPO showed a considerable drop in mRNA expression of Bcl-2 at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus that of CPO treatment alone. Conversely, a highly marked up-regulation was observed in Bax mRNA expression in mice treated with GCar, CPO and GCar-CPO in comparison with that in the control EST-bearing group (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Moreover, highly marked increments were exhibited in mRNA expression for caspase-3, &#x02212;&#x02009;8 and&#x02009;&#x02212;&#x02009;9 in mice treated with GCar, CPO and GCar-CPO versus that of the control EST-bearing group (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).
<fig id="Fig5"><label>Fig. 5</label><caption><p>Effects of CPO, GCar and GCar-CPO on the mRNA expression of Bcl-2, Bax, caspase-3, caspase-8 and caspase-9 in the tumor tissue. Values are expressed as means &#x000b1; SD of triplicate experiments. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig5_HTML" id="MO5"/></fig></p><p id="Par75">Immunohistochemistry analysis was conducted to confirm the effects of GCar on apoptosis-related proteins. The results revealed that GCar administration induced up-regulation of Bax and caspase-3, and down-regulation of Bcl-2 compared to that of the EST-bearing group (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Furthermore, as expected, CPO treatment induced up-regulation of Bax and caspase-3, and down-regulation of Bcl-2 compared to that of the EST-bearing group. The same effects were found in the GCar-CPO treated group.
<fig id="Fig6"><label>Fig. 6</label><caption><p>Figures show apoptotic proteins immunoreactivity in tumor tissues obtained from mice. All magnifications at &#x000d7;&#x02009;400</p></caption><graphic xlink:href="12906_2021_3305_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec21"><title>Oxidative stress biomarkers</title><p id="Par76">As expected, a marked elevation in MDA level was found in the CPO-treated group, compared to that in the EST-bearing mice (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). However, MDA levels markedly declined in the combination treatment group, compared with that in the CPO group, demonstrating the antioxidant effect of cardamom. In addition, a marked elevation in NO levels was shown in the CPO-treated mice compared with that in the EST-bearing mice. Conversely, NO levels declined non-significantly in the GCar group, but significantly increased in the GCar-CPO group compared to that in the EST-bearing mice. GSH levels decreased in the GCar group compared with that in the EST-bearing mice; however, this decrease did not achieve statistical significance. A marked diminishes in GSH levels was observed in the CPO and GCar-CPO-treated mice compared with that in the EST-bearing mice (Fig. <xref rid="Fig7" ref-type="fig">7</xref>).
<fig id="Fig7"><label>Fig. 7</label><caption><p>Effects of CPO, GCar and GCar-CPO on the LPO, NO and GSH levels in the tumor tissue. Values are expressed as means &#x000b1; SD. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig7_HTML" id="MO7"/></fig></p><p id="Par77">A significant rise in SOD and GPx activities in EST-treated groups with GCar treatment alone was recorded in comparison to its level in the EST control group. On contrary, there was a marked reduction in antioxidant enzyme activities in the EST&#x02013;CPO-treated mice in comparison to its levels in the EST-control mice (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). Additionally, treatment of EST bearing mice with GCar and GCar-CPO exhibited a marked increase in antioxidant enzyme activities compared to that of CPO treatment alone.
<fig id="Fig8"><label>Fig. 8</label><caption><p>Effects of CPO, GCar and GCar-CPO on the SOD, CAT, GPx and GR activities in the tumor tissue. Values are expressed as means &#x000b1; SD. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig8_HTML" id="MO8"/></fig></p></sec><sec id="Sec22"><title>Liver and kidney functions results</title><p id="Par78">A non-significant change in liver and kidney function biomarkers were recorded in EST-treated groups with GCar treatment alone. However, there was a marked raise in those biomarkers observed in the CPO-treated mice in comparison to levels in the EST-control mice. On contrary, treatment of EST-bearing mice with GCar combined with CPO exhibited a marked decline in these biomarkers compared to those of the CPO treatment group alone (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>) suggesting the protective effect of cardamom against CPO.
<fig id="Fig9"><label>Fig. 9</label><caption><p>Effects of CPO, GCar and GCar-CPO on the ALT and AST activities and urea and creatinine levels in the serum. Values are expressed as means &#x000b1; SD. a and b: Significant against control and CPO groups at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively</p></caption><graphic xlink:href="12906_2021_3305_Fig9_HTML" id="MO9"/></fig></p></sec></sec><sec id="Sec23"><title>Discussion</title><p id="Par79">The findings of the current investigation showed the importance of GCar as an antitumor agent obtained from natural sources whether used alone or combined with an anticancer drug. The anticancer agent suppressed the propagation of tumor cells by enhancing apoptosis and may represent a beneficial mechanistic strategy to both cancer chemoprevention and chemotherapy [<xref ref-type="bibr" rid="CR28">28</xref>]. The results revealed that GCar displayed antitumor effect against EST tumors in mice, exhibited by the reduction in tumor weight and volume. The decline in body weight gain and diminish in tumor volume are the criteria for judging the efficacy of any anti-tumor drugs [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par80">Growing body of evidences indicate that medicinal plants can modulate various molecular pathways involved in tumor initiation and growth. It is expected that researches with natural products will discover a diversity of molecular mechanisms and targets for tumor growth inhibition, apoptosis and especially angiogenesis prevention. To date, clinical trials in chemoprevention using medicinal products conducted for cancer are very limited. Extensive clinical study is warranted to assess further safety and chemo-preventive efficiency of natural products either alone or in combination with chemotherapeutic drugs against tumor [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par81">Therapeutic molecules that targeted the cell death signaling, including pro-apoptotic proteins stimulators or suppressors of anti-apoptotic protein, could conquer the dilemma of resistance through directing the cancerous cells to self-destruct [<xref ref-type="bibr" rid="CR29">29</xref>]. In this context, the examination of novel targeted apoptotic enhancers for cancerous cells could present a new approach in tumor treatment [<xref ref-type="bibr" rid="CR5">5</xref>]. Accordingly, the goal of the present investigation was to study the apoptotic stimulating effect of GCar on cancer cells relative to their effects on the expression of pro-apoptotic and anti-apoptotic genes, as well as to assess the anticancer potential of GCar against a selected reference anticancer drug, CPO, in an in vivo EST model.</p><p id="Par82">DNA is the principal target in terms of the teratogenic, mutagenic and antineoplastic effects of CPO. Effects of CPO on DNA have been extensively reported in mammalian cells, both of somatic and germ cell origins [<xref ref-type="bibr" rid="CR30">30</xref>]. CPO is supposed to bring its cytotoxicity via the cross-linking of somatic DNA and researchers have found that following CPO treatment there is an occurrence of inter-strand and DNA-protein cross-links, but no single strand breaks [<xref ref-type="bibr" rid="CR31">31</xref>]. CPO suppresses embryonic DNA biosynthesis and does so prior to its effect on RNA or protein construction [<xref ref-type="bibr" rid="CR32">32</xref>]. Although CPO is known to cause DNA cross-links, other DNA damage is produced as well. CPO mediates G0/G1 and S phase arrest [<xref ref-type="bibr" rid="CR33">33</xref>], accumulation of cells in the G0/G1 phase in comparison to that of the control, whereas higher amounts of CPO causes dose-dependent G0/G1, S and G2/M phase inhibition [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par83">The cytotoxic action of CPO is induced mostly because of PM, which causes DNA cross-linking [<xref ref-type="bibr" rid="CR35">35</xref>]. Alkylation of DNA and proteins by CPO causes the creation of cross-links. Cross-links in transcriptional active regions of the DNA can cause a silence or arrest of the RNA polymerases, negatively affecting transcription elongation and genes expression [<xref ref-type="bibr" rid="CR36">36</xref>]. PM is a bifunctional alkylating molecule that binds to the N-7 position of guanine [<xref ref-type="bibr" rid="CR37">37</xref>], to the phosphate backbone of DNA [<xref ref-type="bibr" rid="CR38">38</xref>]. Exposure of cells to PM results in the generation of a mixture of inter-strand, DNA-protein cross-links and enlargement of cells. PM devastates quickly dividing cells and stimulates the DNA double strand break marker, &#x003b3;H2AX and DNA repair in rat granulosa cells and neonatal ovaries [<xref ref-type="bibr" rid="CR39">39</xref>]. Acrolein, on the contrary, is found to bind to proteins, form DNA adducts, generate basic sites and to induce DNA single-strand breaks (SSB) [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par84">CPO causes overproduction of ROS, such as the superoxide anions and hydroxyl radicals, which depletes GSH content and suppresses the activities of antioxidant enzyme in renal tissue. ROS may lead to cellular damage and necrosis via several mechanisms, including peroxidation of cellular membrane phospholipids, proteins denaturation and DNA injury [<xref ref-type="bibr" rid="CR41">41</xref>]. Studies show that CPO induces ROS generation in vivo, which is accountable for the severe unfavorable effects of CPO treatment, including liver and kidney toxicities, which in turn are restrained by supplementation with antioxidants [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par85">In the current study, CPO increased levels of LPO and decreased the GSH content in Ehrlich solid tumor-bearing mice. The antitumor activity of CPO was accompanied with the increase of oxidative stress status in tumor tissue. In rats, CPO increased LPO and altered the -SH status of the tissues with simultaneous alterations in enzymatic antioxidant molecules in other studies [<xref ref-type="bibr" rid="CR43">43</xref>]. GSH content and GR activity are significantly diminished after CPO therapy, whereas GPx and CAT showed a significant improvement in the current study.</p><p id="Par86">CPO-induced production of ROS has also been implicated in its direct cellular toxicity [<xref ref-type="bibr" rid="CR44">44</xref>]. Acrolein, a reactive aldehyde, is known to be the most toxic metabolite of CPO, through its ability to produce toxic ROS and consequently affect surrounding tissues. ROS have various effects, including suppression of a variety of enzymes, membrane and DNA damage and lipid peroxidation [<xref ref-type="bibr" rid="CR45">45</xref>]. In this regard, CPO injury can be ameliorated by free radical scavengers [<xref ref-type="bibr" rid="CR46">46</xref>]. Our study is in agreement with the findings of Kurauchi et al. who found that CPO-induced cardiac apoptosis involves several pathways, including oxidant damage, creation of intrinsic and extrinsic apoptotic cascades and endonucleases [<xref ref-type="bibr" rid="CR47">47</xref>]. Interestingly, we demonstrated that the treatment with GCar showed a significant reduction in oxidative stress markers and activation of the endogenous antioxidant system that affected by EST, suggesting that counteracting oxidative stress is critical in avoiding the progress of EST. The obtained results are in conformity with previous studies on GCar that showed the antioxidant activity in diethylnitrosamine-induced hepatocellular carcinoma [<xref ref-type="bibr" rid="CR48">48</xref>]. Also, the attenuation of oxidative stress by GCar was expressed in its ability to restrain lipid peroxidation due to the presence of polyphenols and flavonoids.</p><p id="Par87">Placzek et al. [<xref ref-type="bibr" rid="CR49">49</xref>] reported that Bcl-2 and Bcl-x<sub>L</sub> anti-apoptotic proteins were minimally expressed following treatment with CPO. Furthermore, the caspase-3, &#x02212;&#x02009;8 and&#x02009;&#x02212;&#x02009;9 are over-expressed in the treated tumor cells and this agreed with the results of Schwartz and Waxman [<xref ref-type="bibr" rid="CR50">50</xref>], suggesting that caspase-9 may mediate apoptosis induced by CPO and its induction could represent a novel approach to the effective treatment of malignant tumors. Moreover, the authors found that Bcl-2 over-expression blocked the cytotoxic actions of activated CPO but did not suppress the drug&#x02019;s cytostatic actions. CPO caused S-phase cell cycle arrest was followed by alteration to an apoptotic pre-G1 state in wild-type 9&#x02009;L cells. In contrast, Bcl-2-expressing 9&#x02009;L cells concentrated in G2/M in response to CPO management [<xref ref-type="bibr" rid="CR50">50</xref>]. In addition, this is in agreement with Yang et al. [<xref ref-type="bibr" rid="CR51">51</xref>], who showed that CPO treatment induced the activation/cleavage of caspase-3 in A431 cells. As a result, CPO treatment can initiate both the extrinsic and intrinsic pathways of caspases activation. Likewise, CPO-induced caspase-3 in Leukemic T cells [<xref ref-type="bibr" rid="CR52">52</xref>] and the authors reported that oxidative stress-induced nuclear translocation of apoptosis-inducing factor (AIF) and endonuclease G (EndoG) in 4-hydroperoxy-CPO (4-OOH-CY)-treated T cells might represent an alternative death pathway in the absence of caspase activity. Other antioxidants such as B12 and sitagliptin, have previously been shown to have antitumor activities [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par88">CPO induced ROS overproduction in vivo, which is accountable to the severe unwanted side effects of CPO treatment, including liver and kidney toxicities, which in turn are depleted by antioxidants addition. However, understanding the expression of anti- and pro-apoptotic proteins and their relationship to the redox system in the cells, as well as the location of ROS production upon CPO therapy will offer precious insights into new approaches for minimizing CPO unwanted side effects without affecting its effectiveness [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par89">GCar has a wide range of biological effects, including anti-diarrheal, anti-hypertensive, anti-arrhythmic, cholesterol lowering, anti-microbial and anti-inflammatory activities [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>]. In addition, GCar caused inhibition of tumor cell proliferation and the induction of apoptosis and the mechanism of antitumor action differs among cell lines [<xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. The anticancer effect of GCar may be attributed to the presence many phenolic compounds such as gallic acid and caffeic acid. GCar possesses a strong antioxidant effect with a ability to restrain the formation of tumors in many cancer models. In this context, Elguindy et al. [<xref ref-type="bibr" rid="CR48">48</xref>] found that GCar treatment markedly diminished the levels of &#x003b1;-feto protein, which revealed the antitumor effect of GCar against hepatocellular carcinoma. Furthermore, Majdalawieh and Carr [<xref ref-type="bibr" rid="CR2">2</xref>] found that GCar markedly promotes the cytotoxic activity of natural killer cells, suggesting its potential anticancer effect and Shinjini Pal et al. [<xref ref-type="bibr" rid="CR58">58</xref>] found that zinc oxide nanoparticles green synthesized by GCar induced apoptosis in HepG2 cells. Moreover, Bhattacharjee and Chatterjee [<xref ref-type="bibr" rid="CR59">59</xref>] observed that eucalyptol, abioactive compound of GCar, bind to Cas-3 and stimulated its activity.</p><p id="Par90">Several cancerous cell lines have been utilized to study the action of GCar and it has been shown to be efficient at relatively low doses on a number of cancers arising from leucocytes, liver, brain, skin, lung, GIT, bone, and breast [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. GCar extracts significantly improve the cytotoxic effect of natural killer cells, representing its anticancer potential [<xref ref-type="bibr" rid="CR2">2</xref>]. The mechanism of its antitumor effect is that GCar modulates a variety of transcription signaling, growth factors, protein kinases and inflammatory cytokines [<xref ref-type="bibr" rid="CR60">60</xref>].</p></sec><sec id="Sec24"><title>Conclusion</title><p id="Par91">In summary, the combined application of GCar with CPO resulted in a statistically significant diminish in cell survival in comparison with GCar or CPO treatment alone. Therefore, the cytotoxic potential of GCar can be amplified by combination with CPO. Furthermore, our finding indicated that GCar is able to initiate apoptosis in cancer cells and maintained the balance between oxidants and antioxidants molecules.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec25"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12906_2021_3305_MOESM1_ESM.docx"><caption><p><bold>Additional file 1: Table S1.</bold> Identification of phytochemical compounds by HPLC in green cardamom (<italic>Elettaria cardamomum</italic>) seeds.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ALT</term><def><p id="Par6">Alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par7">Aspartate aminotransferase</p></def></def-item><def-item><term>Bax</term><def><p id="Par8">Bcl-2-like protein 4</p></def></def-item><def-item><term>Bcl-2</term><def><p id="Par9">B-cell lymphoma 2</p></def></def-item><def-item><term>BW</term><def><p id="Par10">Body weight</p></def></def-item><def-item><term>CAT</term><def><p id="Par11">Catalase</p></def></def-item><def-item><term>CPO</term><def><p id="Par12">Cyclophosphamide</p></def></def-item><def-item><term>EAC</term><def><p id="Par13">Ehrlich Ascites carcinoma</p></def></def-item><def-item><term>EST</term><def><p id="Par14">Ehrlich solid tumor</p></def></def-item><def-item><term>GCar</term><def><p id="Par15">Green cardamom</p></def></def-item><def-item><term>GPx</term><def><p id="Par16">Glutathione peroxidase</p></def></def-item><def-item><term>GR</term><def><p id="Par17">Glutathione reductase</p></def></def-item><def-item><term>GSH</term><def><p id="Par18">Glutathione</p></def></def-item><def-item><term>H&#x00026;E</term><def><p id="Par19">Hematoxylin and Eosin</p></def></def-item><def-item><term>i.m.</term><def><p id="Par20">Intramuscular</p></def></def-item><def-item><term>ILS %</term><def><p id="Par21">Increased in life span percent</p></def></def-item><def-item><term>LPO</term><def><p id="Par22">Lipid peroxidation</p></def></def-item><def-item><term>MDA</term><def><p id="Par23">Malonaldehyde</p></def></def-item><def-item><term>MST</term><def><p id="Par24">Mean survival time</p></def></def-item><def-item><term>NO</term><def><p id="Par25">Nitric oxide</p></def></def-item><def-item><term>PCR</term><def><p id="Par26">Polymerase chain reaction</p></def></def-item><def-item><term>ROS</term><def><p id="Par27">Reactive oxygen species</p></def></def-item><def-item><term>SOD</term><def><p id="Par28">Superoxide dismutase</p></def></def-item><def-item><term>TNF</term><def><p id="Par29">tumor necrosis factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the Research Group No. RG-1441-306.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>RA designed the project. RA and MA performed the experiments, analyzed the data, interpreted the data, drafted and edited the manuscript. NA and GA supplied the chemicals and reagents. All authors read and approved the final draft.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the Deanship of Scientific Research at King Saud University for funding the work through the Research Group No. RG-1441-306.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All relevant data are within the paper.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par92">All experimental protocols were in accordance with the handling and care of animals at Princess Nourah bint Abdulrahman University (Approval number: H-01-R-059/19&#x02013;0272, Riyadh, Saudi Arabia).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par93">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par94">All authors mentioned no conflicts of interest in this research.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amissah-Arthur</surname><given-names>MB</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name></person-group><article-title>Contemporary treatment of systemic lupus erythematosus: an update for clinicians</article-title><source>Ther Adv Chronic Dis</source><year>2010</year><volume>1</volume><issue>4</issue><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1177/2040622310380100</pub-id><?supplied-pmid 23251736?><pub-id pub-id-type="pmid">23251736</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majdalawieh</surname><given-names>AF</given-names></name><name><surname>Carr</surname><given-names>RI</given-names></name></person-group><article-title>In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (Piper nigrum) and cardamom (Elettaria cardamomum)</article-title><source>J Med Food</source><year>2010</year><volume>13</volume><issue>2</issue><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1089/jmf.2009.1131</pub-id><?supplied-pmid 20210607?><pub-id pub-id-type="pmid">20210607</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname><given-names>DF</given-names></name><name><surname>Saleh</surname><given-names>DO</given-names></name><name><surname>Mostafa</surname><given-names>RE</given-names></name></person-group><article-title>Genistein ameliorates cyclophosphamide - induced hepatotoxicity by modulation of oxidative stress and inflammatory mediators</article-title><source>Open Access Maced J Med Sci</source><year>2017</year><volume>5</volume><issue>7</issue><fpage>836</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.3889/oamjms.2017.093</pub-id><?supplied-pmid 29362606?><pub-id pub-id-type="pmid">29362606</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherif</surname><given-names>IO</given-names></name></person-group><article-title>The effect of natural antioxidants in cyclophosphamide-induced hepatotoxicity: role of Nrf2/HO-1 pathway</article-title><source>Int Immunopharmacol</source><year>2018</year><volume>61</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.05.007</pub-id><?supplied-pmid 29800788?><pub-id pub-id-type="pmid">29800788</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Garawani</surname><given-names>IM</given-names></name><name><surname>Elkhateeb</surname><given-names>WA</given-names></name><name><surname>Zaghlol</surname><given-names>GM</given-names></name><name><surname>Almeer</surname><given-names>RS</given-names></name><name><surname>Ahmed</surname><given-names>EF</given-names></name><name><surname>Rateb</surname><given-names>ME</given-names></name><name><surname>Abdel Moneim</surname><given-names>AE</given-names></name></person-group><article-title>Candelariella vitellina extract triggers in vitro and in vivo cell death through induction of apoptosis: a novel anticancer agent</article-title><source>Food Chem Toxicol</source><year>2019</year><volume>127</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2019.03.003</pub-id><?supplied-pmid 30853555?><pub-id pub-id-type="pmid">30853555</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Ashokkumar K, Murugan M, Dhanya MK, Raj S, Kamaraj D. Phytochemical variations among four distinct varieties of Indian cardamom <italic>Elettaria cardamomum</italic> (L.) Maton. Nat Prod Res. 2019:1&#x02013;4. 10.1080/14786419.2018.1561687.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vutakuri</surname><given-names>N</given-names></name><name><surname>Somara</surname><given-names>S</given-names></name></person-group><article-title>Natural and herbal medicine for breast cancer using Elettaria cardamomum (L.) Maton</article-title><source>Int J Herbal Med</source><year>2018</year><volume>6</volume><issue>2</issue><fpage>91</fpage><lpage>96</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuyumcu Savan</surname><given-names>E</given-names></name><name><surname>K&#x000fc;&#x000e7;&#x000fc;kbay</surname><given-names>FZ</given-names></name></person-group><article-title>Essential oil composition of <italic>Elettaria cardamomum</italic> Maton</article-title><source>J Appl Biol Sci</source><year>2013</year><volume>7</volume><fpage>42</fpage><lpage>45</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>I</given-names></name><name><surname>Acharya</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>DL</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Permaul</surname><given-names>E</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>T</given-names></name></person-group><article-title>Antioxidative effects of the spice cardamom against non-melanoma skin cancer by modulating nuclear factor erythroid-2-related factor 2 and NF-kappaB signalling pathways</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><issue>6</issue><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1017/S0007114511006283</pub-id><?supplied-pmid 22182368?><pub-id pub-id-type="pmid">22182368</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>MM</given-names></name><name><surname>Alam</surname><given-names>MN</given-names></name><name><surname>Ulla</surname><given-names>A</given-names></name><name><surname>Sumi</surname><given-names>FA</given-names></name><name><surname>Subhan</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Sikder</surname><given-names>B</given-names></name><name><surname>Hossain</surname><given-names>H</given-names></name><name><surname>Reza</surname><given-names>HM</given-names></name><name><surname>Alam</surname><given-names>MA</given-names></name></person-group><article-title>Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats</article-title><source>Lipids Health Dis</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.1186/s12944-017-0539-x</pub-id><?supplied-pmid 28806968?><pub-id pub-id-type="pmid">28806968</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>KP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Nair</surname><given-names>KP</given-names></name></person-group><article-title>Pharmacological Properties of Cardamom</article-title><source>The Geography of Cardamom (<italic>Elettaria cardamomum</italic> M.): The &#x0201c;Queen&#x0201d; of Spices</source><year>2020</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer International Publishing</publisher-name><fpage>227</fpage><lpage>243</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>S</given-names></name><name><surname>Rana</surname><given-names>T</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name></person-group><article-title>Inhibition of lipid peroxidation and enhancement of GST activity by cardamom and cinnamon during chemically induced colon carcinogenesis in Swiss albino mice</article-title><source>Asian Pac J Cancer Prevent</source><year>2007</year><volume>8</volume><issue>4</issue><fpage>578</fpage><lpage>582</lpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoumi-Ardakani</surname><given-names>Y</given-names></name><name><surname>Mahmoudvand</surname><given-names>H</given-names></name><name><surname>Mirzaei</surname><given-names>A</given-names></name><name><surname>Esmaeilpour</surname><given-names>K</given-names></name><name><surname>Ghazvini</surname><given-names>H</given-names></name><name><surname>Khalifeh</surname><given-names>S</given-names></name><name><surname>Sepehri</surname><given-names>G</given-names></name></person-group><article-title>The effect of Elettaria cardamomum extract on anxiety-like behavior in a rat model of post-traumatic stress disorder</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>87</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.116</pub-id><?supplied-pmid 28073098?><pub-id pub-id-type="pmid">28073098</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Taweel</surname><given-names>GM</given-names></name></person-group><article-title>Cardamom (Elettaria cardamomum) perinatal exposure effects on the development, behavior and biochemical parameters in mice offspring</article-title><source>Saudi J Biol Sci</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2017.08.012</pub-id><?supplied-pmid 29379379?><pub-id pub-id-type="pmid">29379379</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeer</surname><given-names>RS</given-names></name><name><surname>Aref</surname><given-names>AM</given-names></name><name><surname>Hussein</surname><given-names>RA</given-names></name><name><surname>Othman</surname><given-names>MS</given-names></name><name><surname>Abdel Moneim</surname><given-names>AE</given-names></name></person-group><article-title>Antitumor potential of Berberine and Cinnamic acid against solid Ehrlich carcinoma in mice</article-title><source>Anticancer Agents Med Chem</source><year>2019</year><volume>19</volume><issue>3</issue><fpage>356</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.2174/1871520618666181116162441</pub-id><?supplied-pmid 30451117?><pub-id pub-id-type="pmid">30451117</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salah</surname><given-names>R</given-names></name><name><surname>Salama</surname><given-names>MF</given-names></name><name><surname>Mahgoub</surname><given-names>HA</given-names></name><name><surname>El-Sherbini</surname><given-names>ES</given-names></name></person-group><article-title>Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice</article-title><source>J Biochem Mol Toxicol</source><year>2021</year><volume>35</volume><issue>2</issue><fpage>e22645</fpage><pub-id pub-id-type="doi">10.1002/jbt.22645</pub-id><?supplied-pmid 33016524?><pub-id pub-id-type="pmid">33016524</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaswant</surname><given-names>M</given-names></name><name><surname>Poudyal</surname><given-names>H</given-names></name><name><surname>Mathai</surname><given-names>ML</given-names></name><name><surname>Ward</surname><given-names>LC</given-names></name><name><surname>Mouatt</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name></person-group><article-title>Green and black cardamom in a diet-induced rat model of metabolic syndrome</article-title><source>Nutrients</source><year>2015</year><volume>7</volume><issue>9</issue><fpage>7691</fpage><lpage>7707</lpage><pub-id pub-id-type="doi">10.3390/nu7095360</pub-id><?supplied-pmid 26378573?><pub-id pub-id-type="pmid">26378573</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Dkhil MA, Abdel Moneim AE, Hafez TA, Mubaraki MA, Mohamed WF, Thagfan FA, et al. Myristica fragrans kernels prevent Paracetamol-induced hepatotoxicity by inducing anti-apoptotic genes and Nrf2/HO-1 pathway. Int J Mol Sci. 2019;20(4). 10.3390/ijms20040993.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>SN</given-names></name><name><surname>Sharma</surname><given-names>C</given-names></name><name><surname>Mahajan</surname><given-names>UB</given-names></name><name><surname>Patil</surname><given-names>CR</given-names></name><name><surname>Agrawal</surname><given-names>YO</given-names></name><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Arya</surname><given-names>DS</given-names></name><name><surname>Ojha</surname><given-names>S</given-names></name></person-group><article-title>Protective effects of cardamom in isoproterenol-induced myocardial infarction in rats</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><issue>11</issue><fpage>27457</fpage><lpage>27469</lpage><pub-id pub-id-type="doi">10.3390/ijms161126040</pub-id><?supplied-pmid 26593900?><pub-id pub-id-type="pmid">26593900</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twelves</surname><given-names>C</given-names></name><name><surname>Souhami</surname><given-names>R</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Goldstone</surname><given-names>A</given-names></name></person-group><article-title>Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation</article-title><source>Cancer Chemother Pharmacol</source><year>1989</year><volume>25</volume><issue>3</issue><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1007/BF00689586</pub-id><?supplied-pmid 2557172?><pub-id pub-id-type="pmid">2557172</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaganathan</surname><given-names>SK</given-names></name><name><surname>Mondhe</surname><given-names>D</given-names></name><name><surname>Wani</surname><given-names>ZA</given-names></name><name><surname>Pal</surname><given-names>HC</given-names></name><name><surname>Mandal</surname><given-names>M</given-names></name></person-group><article-title>Effect of honey and eugenol on Ehrlich ascites and solid carcinoma</article-title><source>J Biomed Biotechnol</source><year>2010</year><volume>2010</volume><fpage>989163</fpage><lpage>989165</lpage><pub-id pub-id-type="doi">10.1155/2010/989163</pub-id><?supplied-pmid 20369055?><pub-id pub-id-type="pmid">20369055</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffl</surname><given-names>MW</given-names></name></person-group><article-title>A new mathematical model for relative quantification in real-time RT-PCR</article-title><source>Nucleic Acids Res</source><year>2001</year><volume>29</volume><issue>9</issue><fpage>e45</fpage><pub-id pub-id-type="doi">10.1093/nar/29.9.e45</pub-id><?supplied-pmid 11328886?><pub-id pub-id-type="pmid">11328886</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitman</surname><given-names>S</given-names></name><name><surname>Frankel</surname><given-names>S</given-names></name></person-group><article-title>A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases</article-title><source>Am J Clin Pathol</source><year>1957</year><volume>28</volume><issue>1</issue><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/ajcp/28.1.56</pub-id><?supplied-pmid 13458125?><pub-id pub-id-type="pmid">13458125</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Eisenburg</surname><given-names>J</given-names></name></person-group><article-title>Serum bilirubin determination in newborn infants. A new micromethod for the determination of serum of plasma bilirubin in newborn infants</article-title><source>Fortschr Med</source><year>1975</year><volume>93</volume><issue>30</issue><fpage>1461</fpage><lpage>1466</lpage><?supplied-pmid 1225803?><pub-id pub-id-type="pmid">1225803</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkawa</surname><given-names>H</given-names></name><name><surname>Ohishi</surname><given-names>N</given-names></name><name><surname>Yagi</surname><given-names>K</given-names></name></person-group><article-title>Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction</article-title><source>Anal Biochem</source><year>1979</year><volume>95</volume><issue>2</issue><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(79)90738-3</pub-id><?supplied-pmid 36810?><pub-id pub-id-type="pmid">36810</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>LC</given-names></name><name><surname>Wagner</surname><given-names>DA</given-names></name><name><surname>Glogowski</surname><given-names>J</given-names></name><name><surname>Skipper</surname><given-names>PL</given-names></name><name><surname>Wishnok</surname><given-names>JS</given-names></name><name><surname>Tannenbaum</surname><given-names>SR</given-names></name></person-group><article-title>Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids</article-title><source>Anal Biochem</source><year>1982</year><volume>126</volume><issue>1</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(82)90118-X</pub-id><?supplied-pmid 7181105?><pub-id pub-id-type="pmid">7181105</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellman</surname><given-names>GL</given-names></name></person-group><article-title>Tissue sulfhydryl groups</article-title><source>Arch Biochem Biophys</source><year>1959</year><volume>82</volume><issue>1</issue><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/0003-9861(59)90090-6</pub-id><?supplied-pmid 13650640?><pub-id pub-id-type="pmid">13650640</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer efficacy of polyphenols and their combinations. Nutrients. 2016;8(9). 10.3390/nu8090552.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkhateeb</surname><given-names>WA</given-names></name><name><surname>Zaghlol</surname><given-names>GM</given-names></name><name><surname>El-Garawani</surname><given-names>IM</given-names></name><name><surname>Ahmed</surname><given-names>EF</given-names></name><name><surname>Rateb</surname><given-names>ME</given-names></name><name><surname>Abdel Moneim</surname><given-names>AE</given-names></name></person-group><article-title>Ganoderma applanatum secondary metabolites induced apoptosis through different pathways: in vivo and in vitro anticancer studies</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>101</volume><fpage>264</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.058</pub-id><?supplied-pmid 29494964?><pub-id pub-id-type="pmid">29494964</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname><given-names>E</given-names></name><name><surname>Lopes</surname><given-names>F</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><name><surname>Nagy</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>RA</given-names></name><name><surname>Mitchell</surname><given-names>RT</given-names></name><name><surname>Spears</surname><given-names>N</given-names></name></person-group><article-title>Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>1773</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-19761-9</pub-id><?supplied-pmid 29379115?><pub-id pub-id-type="pmid">29379115</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Malayappan</surname><given-names>B</given-names></name><name><surname>Tretyakova</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>MacMillan</surname><given-names>ML</given-names></name><name><surname>Wagner</surname><given-names>JE</given-names></name><name><surname>Jacobson</surname><given-names>PA</given-names></name></person-group><article-title>Formation of cyclophosphamide specific DNA adducts in hematological diseases</article-title><source>Pediatr Blood Cancer</source><year>2012</year><volume>58</volume><issue>5</issue><fpage>708</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/pbc.23254</pub-id><?supplied-pmid 21793181?><pub-id pub-id-type="pmid">21793181</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>RD</given-names></name><name><surname>Rao</surname><given-names>KS</given-names></name><name><surname>Gibson</surname><given-names>JE</given-names></name></person-group><article-title>The in vivo biosynthesis of DNA, RNA, and proteins by mouse embryos after a teratogenic dose of cyclophosphamide</article-title><source>Teratology</source><year>1972</year><volume>6</volume><issue>2</issue><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1002/tera.1420060203</pub-id><?supplied-pmid 5079703?><pub-id pub-id-type="pmid">5079703</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>T</given-names></name></person-group><article-title>DNA damage induced by alkylating agents and repair pathways</article-title><source>J Nucleic Acids</source><year>2010</year><volume>2010</volume><fpage>543531</fpage><lpage>543537</lpage><pub-id pub-id-type="doi">10.4061/2010/543531</pub-id><?supplied-pmid 21113301?><pub-id pub-id-type="pmid">21113301</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Singh N, Nigam M, Ranjan V, Sharma R, Balapure AK, Rath SK (2009) Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. J Pharmacol Sci 109(4):473&#x02013;485. Doi: JST.JSTAGE/jphs/08173FP.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>ME</given-names></name><name><surname>Huitema</surname><given-names>AD</given-names></name><name><surname>Rodenhuis</surname><given-names>S</given-names></name><name><surname>Beijnen</surname><given-names>JH</given-names></name></person-group><article-title>Clinical pharmacokinetics of cyclophosphamide</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><issue>11</issue><fpage>1135</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544110-00003</pub-id><?supplied-pmid 16231966?><pub-id pub-id-type="pmid">16231966</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Mahecha</surname><given-names>A</given-names></name><name><surname>Hales</surname><given-names>BF</given-names></name><name><surname>Robaire</surname><given-names>B</given-names></name></person-group><article-title>Chronic cyclophosphamide treatment alters the expression of stress response genes in rat male germ Cells1</article-title><source>Biol Reprod</source><year>2002</year><volume>66</volume><issue>4</issue><fpage>1024</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1095/biolreprod66.4.1024</pub-id><?supplied-pmid 11906922?><pub-id pub-id-type="pmid">11906922</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malayappan</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Nie</surname><given-names>B</given-names></name><name><surname>Panchal</surname><given-names>D</given-names></name><name><surname>Matter</surname><given-names>B</given-names></name><name><surname>Jacobson</surname><given-names>P</given-names></name><name><surname>Tretyakova</surname><given-names>N</given-names></name></person-group><article-title>Quantitative high-performance liquid chromatography&#x02212;electrospray ionization tandem mass spectrometry analysis of Bis-N7-guanine DNA&#x02212;DNA cross-links in white blood cells of Cancer patients receiving cyclophosphamide therapy</article-title><source>Anal Chem</source><year>2010</year><volume>82</volume><issue>9</issue><fpage>3650</fpage><lpage>3658</lpage><pub-id pub-id-type="doi">10.1021/ac902923s</pub-id><?supplied-pmid 20361772?><pub-id pub-id-type="pmid">20361772</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>ZW</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Chen</surname><given-names>YZ</given-names></name></person-group><article-title>Mechanisms of drug combinations: interaction and network perspectives</article-title><source>Nat Rev Drug Discov</source><year>2009</year><volume>8</volume><issue>2</issue><fpage>111</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/nrd2683</pub-id><?supplied-pmid 19180105?><pub-id pub-id-type="pmid">19180105</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Nteeba</surname><given-names>J</given-names></name><name><surname>Madden</surname><given-names>JA</given-names></name><name><surname>Keating</surname><given-names>AF</given-names></name></person-group><article-title>Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice</article-title><source>Biol Reprod</source><year>2017</year><volume>96</volume><fpage>491</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1095/biolreprod.116.143800</pub-id><pub-id pub-id-type="pmid">28203708</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvakumar</surname><given-names>E</given-names></name><name><surname>Prahalathan</surname><given-names>C</given-names></name><name><surname>Mythili</surname><given-names>Y</given-names></name><name><surname>Varalakshmi</surname><given-names>P</given-names></name></person-group><article-title>Beneficial effects of dl-&#x003b1;-lipoic acid on cyclophosphamide-induced oxidative stress in mitochondrial fractions of rat testis</article-title><source>Chem Biol Interact</source><year>2005</year><volume>152</volume><issue>1</issue><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2005.01.009</pub-id><?supplied-pmid 15766923?><pub-id pub-id-type="pmid">15766923</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora Lde</surname><given-names>O</given-names></name><name><surname>Antunes</surname><given-names>LM</given-names></name><name><surname>Francescato</surname><given-names>HD</given-names></name><name><surname>Bianchi Mde</surname><given-names>L</given-names></name></person-group><article-title>The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats</article-title><source>Pharmacol Res</source><year>2003</year><volume>47</volume><issue>6</issue><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/S1043-6618(03)00040-9</pub-id><?supplied-pmid 12742005?><pub-id pub-id-type="pmid">12742005</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caglayan</surname><given-names>C</given-names></name><name><surname>Temel</surname><given-names>Y</given-names></name><name><surname>Kandemir</surname><given-names>FM</given-names></name><name><surname>Yildirim</surname><given-names>S</given-names></name><name><surname>Kucukler</surname><given-names>S</given-names></name></person-group><article-title>Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage</article-title><source>Environ Sci Pollut Res Int</source><year>2018</year><volume>25</volume><issue>21</issue><fpage>20968</fpage><lpage>20984</lpage><pub-id pub-id-type="doi">10.1007/s11356-018-2242-5</pub-id><?supplied-pmid 29766429?><pub-id pub-id-type="pmid">29766429</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olayinka</surname><given-names>ET</given-names></name><name><surname>Ore</surname><given-names>A</given-names></name><name><surname>Ola</surname><given-names>OS</given-names></name><name><surname>Adeyemo</surname><given-names>OA</given-names></name></person-group><article-title>Ameliorative effect of Gallic acid on cyclophosphamide-induced oxidative injury and hepatic dysfunction in rats</article-title><source>Med Sci</source><year>2015</year><volume>3</volume><issue>3</issue><fpage>78</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.3390/medsci3030078</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeelani</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>SN</given-names></name><name><surname>Shaeib</surname><given-names>F</given-names></name><name><surname>Kohan-Ghadr</surname><given-names>HR</given-names></name><name><surname>Aldhaheri</surname><given-names>SR</given-names></name><name><surname>Najafi</surname><given-names>T</given-names></name><name><surname>Thakur</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>R</given-names></name><name><surname>Abu-Soud</surname><given-names>HM</given-names></name></person-group><article-title>Cyclophosphamide and acrolein induced oxidative stress leading to deterioration of metaphase II mouse oocyte quality</article-title><source>Free Radical Biol Med</source><year>2017</year><volume>110</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.05.006</pub-id><pub-id pub-id-type="pmid">28499912</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>WS</given-names></name><name><surname>Deng</surname><given-names>YH</given-names></name><name><surname>Cui</surname><given-names>FC</given-names></name></person-group><article-title>Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression</article-title><source>Arch Med Sci</source><year>2016</year><volume>12</volume><issue>4</issue><fpage>871</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.5114/aoms.2016.59919</pub-id><?supplied-pmid 27478470?><pub-id pub-id-type="pmid">27478470</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>EJ</given-names></name><name><surname>Peterson</surname><given-names>A</given-names></name><name><surname>Malley</surname><given-names>S</given-names></name><name><surname>Daniel</surname><given-names>M</given-names></name><name><surname>Lambert</surname><given-names>D</given-names></name><name><surname>Kosofsky</surname><given-names>M</given-names></name><name><surname>Vizzard</surname><given-names>MA</given-names></name></person-group><article-title>The effects of tempol on cyclophosphamide-induced oxidative stress in rat micturition reflexes</article-title><source>Sci World J</source><year>2015</year><volume>2015</volume><fpage>545048</fpage><lpage>545013</lpage><pub-id pub-id-type="doi">10.1155/2015/545048</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurauchi</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Miyahara</surname><given-names>E</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name></person-group><article-title>Role of metabolites of cyclophosphamide in cardiotoxicity</article-title><source>BMC Res Notes</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>406</fpage><pub-id pub-id-type="doi">10.1186/s13104-017-2726-2</pub-id><?supplied-pmid 28807058?><pub-id pub-id-type="pmid">28807058</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elguindy</surname><given-names>NM</given-names></name><name><surname>Yacout</surname><given-names>GA</given-names></name><name><surname>El Azab</surname><given-names>EF</given-names></name><name><surname>Maghraby</surname><given-names>HK</given-names></name></person-group><article-title>Chemoprotective effect of Elettaria Cardamomum against chemically induced hepatocellular carcinoma in rats by inhibiting NF-&#x003ba;B, oxidative stress, and activity of ornithine decarboxylase</article-title><source>S Afr J Bot</source><year>2016</year><volume>105</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.sajb.2016.04.001</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Placzek</surname><given-names>WJ</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Kitada</surname><given-names>S</given-names></name><name><surname>Zhai</surname><given-names>D</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Pellecchia</surname><given-names>M</given-names></name></person-group><article-title>A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy</article-title><source>Cell Death Dis</source><year>2010</year><volume>1</volume><fpage>e40</fpage><pub-id pub-id-type="doi">10.1038/cddis.2010.18</pub-id><?supplied-pmid 21364647?><pub-id pub-id-type="pmid">21364647</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>PS</given-names></name><name><surname>Waxman</surname><given-names>DJ</given-names></name></person-group><article-title>Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells</article-title><source>Mol Pharmacol</source><year>2001</year><volume>60</volume><issue>6</issue><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1124/mol.60.6.1268</pub-id><?supplied-pmid 11723234?><pub-id pub-id-type="pmid">11723234</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><article-title>Cyclophosphamide-induced apoptosis in A431 cells is inhibited by fucosyltransferase IV</article-title><source>J Cell Biochem</source><year>2011</year><volume>112</volume><issue>5</issue><fpage>1376</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1002/jcb.23054</pub-id><?supplied-pmid 21337384?><pub-id pub-id-type="pmid">21337384</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>G</given-names></name><name><surname>Westhoff</surname><given-names>MA</given-names></name><name><surname>Fischer-Posovszky</surname><given-names>P</given-names></name><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Schanbacher</surname><given-names>M</given-names></name><name><surname>Eckhoff</surname><given-names>SM</given-names></name><name><surname>Stahnke</surname><given-names>K</given-names></name><name><surname>Vahsen</surname><given-names>N</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name></person-group><article-title>4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG</article-title><source>Cell Death Differ</source><year>2007</year><volume>15</volume><issue>2</issue><fpage>332</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402272</pub-id><?supplied-pmid 18034189?><pub-id pub-id-type="pmid">18034189</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Sun D, Sun C, Qiu C, Yao L, Yu J, Al Sberi H, Fouda MS, Othman MS, Lokman MS, Kassab RB, Abdel Moneim AE. Allicin mitigates hepatic injury following cyclophosphamide administration via activation of Nrf2/ARE pathways and through inhibition of inflammatory and apoptotic machinery. Environ Sci Pollut Res Int.&#x000a0;2021. 10.1007/s11356-021-13392-w.</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiblawi</surname><given-names>S</given-names></name><name><surname>Dhanarasu</surname><given-names>S</given-names></name><name><surname>Faris</surname><given-names>MA</given-names></name></person-group><article-title>Chemopreventive effect of cardamom (Elettaria cardamomum L.) against Benzo (alpha)Pyrene-induced Forestomach Papillomagenesis in Swiss albino mice</article-title><source>J Environ Pathol Toxicol Oncol</source><year>2015</year><volume>34</volume><issue>2</issue><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1615/jenvironpatholtoxicoloncol.2015010838</pub-id><?supplied-pmid 26081028?><pub-id pub-id-type="pmid">26081028</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhihua</surname><given-names>Z</given-names></name><name><surname>Jianping</surname><given-names>Y</given-names></name><name><surname>Miaomiao</surname><given-names>S</given-names></name><name><surname>Kuisheng</surname><given-names>C</given-names></name></person-group><article-title>Exploration for the multi-effect of cardamom in&#x02019;s resistance to multiple myeloma</article-title><source>Pak J Pharm Sci</source><year>2014</year><volume>27</volume><issue>6 Suppl</issue><fpage>2001</fpage><lpage>2006</lpage><?supplied-pmid 25410063?><pub-id pub-id-type="pmid">25410063</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiblawi</surname><given-names>S</given-names></name><name><surname>Al-Hazimi</surname><given-names>A</given-names></name><name><surname>Al-Mogbel</surname><given-names>M</given-names></name><name><surname>Hossain</surname><given-names>A</given-names></name><name><surname>Bagchi</surname><given-names>D</given-names></name></person-group><article-title>Chemopreventive effects of cardamom (Elettaria cardamomum L.) on chemically induced skin carcinogenesis in Swiss albino mice</article-title><source>J Med Food</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>576</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1089/jmf.2011.0266</pub-id><?supplied-pmid 22404574?><pub-id pub-id-type="pmid">22404574</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneshi-Maskooni</surname><given-names>M</given-names></name><name><surname>Keshavarz</surname><given-names>SA</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Badri-Fariman</surname><given-names>M</given-names></name><name><surname>Jazayeri-Tehrani</surname><given-names>SA</given-names></name><name><surname>Sotoudeh</surname><given-names>G</given-names></name></person-group><article-title>The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>260</fpage><pub-id pub-id-type="doi">10.1186/s13063-017-1979-3</pub-id><?supplied-pmid 28592311?><pub-id pub-id-type="pmid">28592311</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Pal S, Pal K, Mukherjee S, Bera D, Karmakar P, D. S (2020) Green cardamom mediated phytosynthesis of ZnONPs and validation of its antibacterial and anticancerous potential. Mater Res Express 7:015068, 1, DOI: 10.1088/2053-1591/ab69c8.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>J</given-names></name></person-group><article-title>Identification of proapoptopic, anti-inflammatory, anti- proliferative, anti-invasive and anti-angiogenic targets of essential oils in cardamom by dual reverse virtual screening and binding pose analysis</article-title><source>Asian Pac J Cancer Prevent</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>3735</fpage><lpage>3742</lpage><pub-id pub-id-type="doi">10.7314/apjcp.2013.14.6.3735</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>VR</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Cancer cell signaling pathways targeted by spice-derived nutraceuticals</article-title><source>Nutr Cancer</source><year>2012</year><volume>64</volume><issue>2</issue><fpage>173</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1080/01635581.2012.630551</pub-id><?supplied-pmid 22149093?><pub-id pub-id-type="pmid">22149093</pub-id></element-citation></ref></ref-list></back></article>